Lv1
20 积分 2023-06-05 加入
Prevalence and molecular correlates of acquired EGFR resistance mutations in non-small cell lung cancer (NSCLC)
10小时前
待确认
Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations
20天前
已完结
Therapeutic effects of an ALK inhibitor, brigatinib, on lung large cell neuroendocrine carcinoma with EML4-ALK fusion
27天前
已完结
Efficacy and Safety of Immunotherapy Combined with Anlotinib as FirstLine Treatment in Older NSCLC Patients with PD-L1 Expression<50
1个月前
已完结
Clinical Significance of 4L Lymph Node Dissection in Left Lung Cancer
1个月前
已完结
YY1‐induced upregulation of FOXP4‐AS1 and FOXP4 promote the proliferation of esophageal squamous cell carcinoma cells
1个月前
已完结
GOPC-ROS1 Rearrangement as an Acquired Resistance Mechanism to Osimertinib and Responding to Crizotinib Combined Treatments in Lung Adenocarcinoma
1个月前
已完结
Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC: A Multi-Center Analysis and Literature Review
1个月前
已完结
Amivantamab (JNJ-61186372) induces clinical, biochemical, molecular, and radiographic response in a treatment-refractory NSCLC patient harboring amplified triple EGFR mutations (L858R/ T790M/G796S) in cis
2个月前
已完结
Osimertinib is an effective epidermal growth factor receptor-tyrosine kinase inhibitor choice for lung cancer with epidermal growth factor receptor exon 18-25 kinase domain duplication: report of two cases
2个月前
已完结
皖公网安备34019202002308
